India, Nov. 19 -- VivoSim Labs (VIVS) announced a seven-figure agreement with a top-10 global pharmaceutical company for its NAMkind liver and intestinal toxicology testing services, prompting the company to expect revenue growth in fiscal 2027 to exceed its previously issued guidance of more than 500%.
Drug developers are increasingly adopting human tissue-based testing methods as an alternative to traditional animal studies, aiming to improve the prediction of drug safety before clinical trials begin.
Testing Program Underway
The agreement covers VivoSim's liver and intestinal toxicology platforms, with work already underway. The company expects revenue from the contract to be recognized during its fiscal third and fourth quarters endi...